Arcus Biosciences (RCUS) Cash & Current Investments (2016 - 2026)

Arcus Biosciences' Cash & Current Investments history runs 11 years deep, the most recent figure standing at $822.0 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 17.55% year-over-year to $822.0 million; the TTM figure through Mar 2026 stood at $822.0 million (down 17.55% YoY), while the FY2025 annual figure was $981.0 million, changed 0.31% from the prior year.
• Cash & Current Investments was $822.0 million for Q1 2026 at Arcus Biosciences, down from $981.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $1.2 billion in Q1 2022 to a low of $759.0 million in Q4 2023.
• Historically, Cash & Current Investments has averaged $968.2 million across 5 years, with a median of $978.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments soared 102.2% in 2022, then decreased 24.78% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $1.0 billion in 2022, then decreased by 24.78% to $759.0 million in 2023, then rose by 28.85% to $978.0 million in 2024, then grew by 0.31% to $981.0 million in 2025, then declined by 16.21% to $822.0 million in 2026.
• The last three Cash & Current Investments figures came in at $822.0 million (Q1 2026), $981.0 million (Q4 2025), and $831.0 million (Q3 2025), per Business Quant data.